Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

Blood Cancer Journal

Volumn 3, Issue 8, 2013, Pages

  Maeda, T ^a   Hosen, N ^a   Fukushima, K ^a   Tsuboi, A ^a   Morimoto, S ^a   Matsui, T ^a   Sata, H ^a   Fujita, J ^a   Hasegawa, K ^a   Nishida, S ^a   Nakata, J ^a   Nakae, Y ^a   Takashima, S ^a   Nakajima, H ^a   Fujiki, F ^a   Tatsumi, N ^a   Kondo, T ^b   Hino, M ^c   Oji, Y ^a   Oka, Y ^a   Kanakura, Y ^a   Kumanogoh, A ^a   Sugiyama, H ^a   more..

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A ANTIGEN; MONTANIDE ISA 51; PREDNISOLONE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; WILMS TUMOR 1 VACCINE; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BRONCHIOLITIS OBLITERANS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOTOXIC LYMPHOCYTE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HYPOXIA; INJECTION SITE INFLAMMATION; LETTER; LEUKEMIA; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; RECURRENCE RISK; VACCINATION;

EID: 84883002342     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.29     Document Type: Letter

References (8)

1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts. N Engl J Med 1979; 300: 1068-1073 (Pubitemid 9198740)
2. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242
3. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121 (Pubitemid 35203456)
4. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409
5. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079 (Pubitemid 24328100)
6. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890 (Pubitemid 39298502)
7. Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012; 26: 1410-1413
8. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-620 (Pubitemid 35440514)